Rosenstock J - Search Results

1

Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes.

Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R; CV181-011 Study Investigators. Rosenstock J, et al. Curr Med Res Opin. 2009 Oct;25(10):2401-11. doi: 10.1185/03007990903178735. Curr Med Res Opin. 2009. PMID: 19650754 Clinical Trial.

2

Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.

Rosenstock J, Samols E, Muchmore DB, Schneider J. Rosenstock J, et al. Diabetes Care. 1996 Nov;19(11):1194-9. doi: 10.2337/diacare.19.11.1194. Diabetes Care. 1996. PMID: 8908379 Clinical Trial.

3

Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.

Rosenstock J, Brown A, Fischer J, Jain A, Littlejohn T, Nadeau D, Sussman A, Taylor T, Krol A, Magner J. Rosenstock J, et al. Diabetes Care. 1998 Dec;21(12):2050-5. doi: 10.2337/diacare.21.12.2050. Diabetes Care. 1998. PMID: 9839093 Clinical Trial.

4

Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

Rosenstock J, Park G, Zimmerman J; U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Rosenstock J, et al. Diabetes Care. 2000 Aug;23(8):1137-42. doi: 10.2337/diacare.23.8.1137. Diabetes Care. 2000. PMID: 10937511 Clinical Trial.

5

Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.

Rosenstock J, Schwartz SL, Clark CM Jr, Park GD, Donley DW, Edwards MB. Rosenstock J, et al. Diabetes Care. 2001 Apr;24(4):631-6. doi: 10.2337/diacare.24.4.631. Diabetes Care. 2001. PMID: 11315821 Clinical Trial.

6

Insulin therapy: optimizing control in type 1 and type 2 diabetes.

Rosenstock J. Rosenstock J. Clin Cornerstone. 2001;4(2):50-64. doi: 10.1016/s1098-3597(01)90029-8. Clin Cornerstone. 2001. PMID: 11838327 Review.

7

Efficacy and safety of pioglitazone in type 2 diabetes: a randomised, placebo-controlled study in patients receiving stable insulin therapy.

Rosenstock J, Einhorn D, Hershon K, Glazer NB, Yu S; Pioglitazone 014 Study Group. Rosenstock J, et al. Int J Clin Pract. 2002 May;56(4):251-7. Int J Clin Pract. 2002. PMID: 12074206 Clinical Trial.

8

Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes.

Rosenstock J, Shen SG, Gatlin MR, Foley JE. Rosenstock J, et al. Diabetes Care. 2002 Sep;25(9):1529-33. doi: 10.2337/diacare.25.9.1529. Diabetes Care. 2002. PMID: 12196422 Clinical Trial.

9

Repaglinide versus nateglinide monotherapy: a randomized, multicenter study.

Rosenstock J, Hassman DR, Madder RD, Brazinsky SA, Farrell J, Khutoryansky N, Hale PM; Repaglinide Versus Nateglinide Comparison Study Group. Rosenstock J, et al. Diabetes Care. 2004 Jun;27(6):1265-70. doi: 10.2337/diacare.27.6.1265. Diabetes Care. 2004. PMID: 15161773 Clinical Trial.

10

Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. SULphonylurea Titration (RESULT) study.

Rosenstock J, Goldstein BJ, Vinik AI, O'neill MC, Porter LE, Heise MA, Kravitz B, Dirani RG, Freed MI; RESULT Study Group. Rosenstock J, et al. Diabetes Obes Metab. 2006 Jan;8(1):49-57. doi: 10.1111/j.1463-1326.2005.00541.x. Diabetes Obes Metab. 2006. PMID: 16367882 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

529 results

Search Page